(1) Cambridge Consultants developed the ground-breaking optics technology powering Ellume's FDA authorized COVID-19 Home Test CAMBRIDGE, United Kingdom and BRISBANE, Australia, March 10, 2021, part of the Capgemini Group. Together, the two companies have developed a next-generation, multi-component reader that combines optics, electronics and software, and powers the core technology behind the Ellume COVID-19 Home Test. Ellume's test is the first rapid self-test for COVID-19 detection granted Emergency Authorization Use by the U.S. FDAfor both asymptomatic and symptomatic use without a prescription. In February, Ellume announced a $231.8 million agreement with the U.S. government, including the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. government's pandemic response and the establishment of Ellume's first U.S. manufacturing facility.